Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Albanell

Showing results (21-30 of 93) with videos related to

Pageof 10
Sort By:
Medicina Clinica|March 16, 1991
[Acute icteric hepatitis and facial paralysis in a female patient with infectious mononucleosis]J Albanell, A de Luis, C Pigrau, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basisJ Bellmunt, N Eres, A Ribas, et al.
Cancer Research|March 30, 1999
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cellsJ Codony-Servat, J Albanell, J C Lopez-Talavera, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 17, 2010
Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patientsD Conde-Estévez, S Grau, J Albanell, et al.
Journal of Cellular Biochemistry|November 5, 1997
Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated proteinT W Reichman, J Albanell, X Wang, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 6, 2005
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatmentC Montagut, A Rovira, B Mellado, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 14, 2010
C-MET as a new therapeutic target for the development of novel anticancer drugsI Cañadas, F Rojo, M Arumí-Uría, et al.
Blood|July 1, 1997
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cellsM Engelhardt, R Kumar, J Albanell, et al.
Anales De Medicina Interna (Madrid, Spain : 1984)|July 1, 1992
[Spinal cord compression as a primary manifestation of occult thyroid carcinoma]P Vicente, A Rovirosa, O Gallego, et al.
Critical Reviews in Oncology/Hematology|August 6, 2003
New drugs and new approaches in metastatic bladder cancerJ Bellmunt, R de Wit, S Albiol, et al.
Pageof 10

Showing results (21-30 of 93) with videos related to

Sort By:
Pageof 10
Medicina Clinica|March 16, 1991
[Acute icteric hepatitis and facial paralysis in a female patient with infectious mononucleosis]J Albanell, A de Luis, C Pigrau, et al.
Cancer Chemotherapy and Pharmacology|January 1, 1997
Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basisJ Bellmunt, N Eres, A Ribas, et al.
Cancer Research|March 30, 1999
Cleavage of the HER2 ectodomain is a pervanadate-activable process that is inhibited by the tissue inhibitor of metalloproteases-1 in breast cancer cellsJ Codony-Servat, J Albanell, J C Lopez-Talavera, et al.
European Journal of Clinical Microbiology & Infectious Diseases : Official Publication of the European Society of Clinical Microbiology|August 17, 2010
Clinical characteristics and outcomes of patients with vancomycin-susceptible Enterococcus faecalis and Enterococcus faecium bacteraemia in cancer patientsD Conde-Estévez, S Grau, J Albanell, et al.
Journal of Cellular Biochemistry|November 5, 1997
Downregulation of telomerase activity in HL60 cells by differentiating agents is accompanied by increased expression of telomerase-associated proteinT W Reichman, J Albanell, X Wang, et al.
Drugs of Today (Barcelona, Spain : 1998)|August 6, 2005
Preclinical and clinical development of the proteasome inhibitor bortezomib in cancer treatmentC Montagut, A Rovira, B Mellado, et al.
Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico|May 14, 2010
C-MET as a new therapeutic target for the development of novel anticancer drugsI Cañadas, F Rojo, M Arumí-Uría, et al.
Blood|July 1, 1997
Telomerase regulation, cell cycle, and telomere stability in primitive hematopoietic cellsM Engelhardt, R Kumar, J Albanell, et al.
Anales De Medicina Interna (Madrid, Spain : 1984)|July 1, 1992
[Spinal cord compression as a primary manifestation of occult thyroid carcinoma]P Vicente, A Rovirosa, O Gallego, et al.
Critical Reviews in Oncology/Hematology|August 6, 2003
New drugs and new approaches in metastatic bladder cancerJ Bellmunt, R de Wit, S Albiol, et al.
Pageof 10